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Abstract: Atrial fibrillation (AF) is the most common age-related cardiac arrhythmia worldwide
and is associated with ischemic stroke, heart failure, and substantial morbidity and mortality. Un-
fortunately, current AF therapy is only moderately effective and does not prevent AF progression
from recurrent intermittent episodes (paroxysmal) to persistent and finally permanent AF. It has
been recognized that AF persistence is related to the presence of electropathology. Electropathology
is defined as structural damage, including degradation of sarcomere structures, in the atrial tissue
which, in turn, impairs electrical conduction and subsequently the contractile function of atrial car-
diomyocytes. Recent research findings indicate that derailed proteostasis underlies structural damage
and, consequently, electrical conduction impairment. A healthy proteostasis is of vital importance for
proper function of cells, including cardiomyocytes. Cells respond to a loss of proteostatic control
by inducing a heat shock response (HSR), which results in heat shock protein (HSP) expression.
Emerging clinical evidence indicates that AF-induced proteostasis derailment is rooted in exhaustion
of HSPs. Cardiomyocytes lose defense against structural damage-inducing pathways, which drives
progression of AF and induction of HSP expression. In particular, small HSPB1 conserves sarcomere
structures by preventing their degradation by proteases, and overexpression of HSPB1 accelerates
recovery from structural damage in experimental AF model systems. In this review, we provide
an overview of the mechanisms of action of HSPs in preventing AF and discuss the therapeutic
potential of HSP-inducing compounds in clinical AF, as well as the potential of HSPs as biomarkers
to discriminate between the various stages of AF and recurrence of AF after treatment.
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1. Introduction
Atrial fibrillation (AF) is the most common age-related cardiac arrhythmia worldwide
and is associated with ischemic stroke [1,2], dementia [3], heart failure [4], and substantial
morbidity and mortality [5]. Prevalence and incidence of AF increase with age and are
higher in men compared with women, although women have increased mortality [6,7].
In 2010, an estimated 8.8 million individuals were registered in the European Union with
AF, and due to the rapid aging of the population, this number is expected to be doubled
by 2060 [5]. AF was originally described as an “electrical” disease and, consequently,
current pharmacological treatments are directed at the electrical refractoriness of the atria.
Unfortunately, these treatments are only moderately effective and do not prevent AF
progression from recurrent intermittent episodes (paroxysmal) to persistent and finally
permanent AF stage. Further, usage of pharmacological therapies is limited by potentially
severe and life-threatening side effects [8]. In addition to the moderate efficacy of current
drug therapies, the current diagnostic tools available have certain limitations to accurately
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stage AF, especially in regard to AF progression [9]. Currently, AF can only be diagnosed
with a surface electrocardiogram when a patient already suffers from AF. Importantly,
the electrocardiogram cannot be used to accurately assess the stage of AF, which is im-
portant to develop personalized therapies. Therefore, there is an urgent need to develop
mechanism-based therapies and identify biomarkers which may help to stage AF.
Several studies have dissected various mechanisms underlying AF. AF persistence is
related to the presence of electropathology, which is defined as structural damage present in
atrial tissue, which impairs electrical conduction and subsequently the contractile function
of atrial cardiomyocytes [8,10–12]. The degree of electropathology is related to the stage
of AF and becomes more severe over time [13]. Despite the efforts of current treatment
modalities to change the electrical refractoriness of atrial cardiomyocytes, the therapies do
not attenuate structural damage and consequently result in accumulation of damage over
time. Structural damage includes loss of sarcomeres and myofibrils (myolysis), disruption
of mitochondria, and DNA damage [14–16]. Deterioration of the cardiomyocytes explains
AF progression and the high number of AF recurrence after treatment [17].
Emerging research findings indicate that derailed proteostasis underlies structural
damage and electrical conduction impairment. A healthy proteostasis is of vital importance
for proper function of cells and organisms [18]. Proteostasis is of particular importance in
long-lived postmitotic cardiomyocytes, since they display limited regenerative capacity.
Proteostasis involves controlling the concentration, conformation, binding interaction,
kinetics, and location of individual proteins [19]. Cells respond to a loss of proteostatic
control by inducing a heat shock response (HSR), which results in heat shock protein (HSP)
expression. The central regulator of the HSR is the Heat Shock Factor 1 (HSF1). This evo-
lutionarily conserved transcription factor becomes trimerized and phosphorylated upon
activation while being transported to the nucleus, where it targets heat-shock-responsive
DNA elements (HSEs) in order to upregulate the HSP genes (Figure 1) [20,21]. Whereas,
under normal physiological conditions, HSF1 is a monomer and mainly present in the
cytosol. HSPs such as HSPA1A and HSPC1 bind to and thereby sequester monomeric
HSF1, resulting in suppression of HSF1 transcriptional activity [21].
It has been recognized that AF-induced proteostasis derailment and subsequent
electropathology is rooted in exhaustion of HSPs. HSPs are chaperones which bind to
misfolded proteins such as cytoskeletal and sarcomere protein structures, and thereby
protect against structural remodeling in AF [14,22–26]. Previous research findings disclosed
that some small HSPs, particularly HSPB1, bind to myofibrils and protect against myofibril
degradation in experimental and clinical AF (Figure 1) [14]. Furthermore, the HSP response
is temporarily activated in patients with short duration of AF but exhausts when AF
persists [14]. Consequently, cardiomyocytes lose defense against structural remodeling,
thus leading to the progression of AF. Based on these findings, clinical trials have been
conducted to test whether HSP inducers can increase HSP levels in human atrial tissue and
blood and represent biomarkers to stage AF. In this review, we provide an overview of the
cardioprotective effects of HSPs in AF and elucidate the molecular pathways. Furthermore,
we discuss the therapeutic potential of HSP-inducing compounds in clinical AF as well as
the potential of HSP as a biomarker to discriminate between the various stages of AF and
to predict recurrence of AF after treatment.
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Figure 1. Overview of cardioprotective actions of heat shock protein (HSP) function in atrial fibrillation (AF). Heat Shock Factor
1 (HSF1), the central regulator of the heat shock response (HSR), trimerizes and is phosphorylated upon activation while being
transported to the nucleus where it binds to the heat-shock-responsive DNA element (HSE) of HSP genes, including HSPB1.
The binding of HSF1 to HSE and sequential expression of HSPs is boosted by geranylgeranylacetone (GGA) and L-glutamine
but attenuated by active Ras homolog gene family member A (RhoA). Within the cytosol, HSPB1 inhibits HDAC6-induced
microtubule degradation by calpain. Furthermore, HSPB1 has a protective function by direct binding to the myofibrils and
shielding them from degradation. HSPA5, located in the endoplasmic reticulum (ER), reduces ER stress and inhibits AF-induced
autophagy. The export of mRNA HSPA1 and import of protein HSPA1 via NUP155 is directly influenced by mutations in
lamin A/C.
2. Exhaustion of HSR Underlies AF
The first discovery of HSPs goes back to 1962. Ritossa described the effect of temper-
ature changes on the puffing patterns of chromosomes isolated from the salivary gland
of Drosophila busckii [27]. Twelve years later, Tissières et al. described specific mRNA
expression linked to the chromosomal puffs to become rapidly transported into the cytosol
and translated into polypeptides upon heat shock [28]. This response is nowadays known
as the HSR, which results in the expression of HSPs. HSPs are ubiquitously expressed
molecular chaperone proteins, which exhibit a high level of conservation across all celled
organisms. HSPs are involved in a plethora of processes such as protein trafficking, protein
folding, and protein complex assembly and therefore play a central role in proteostasis
and healthy function of cells [29]. Moreover, HSPs are particularly induced during physio-
logical stress to maintain protein quality control by either refolding misfolded proteins or
channeling them to the ubiquitin proteolysis pathway for degradation in order to combat
stress-induced protein misfolding [30].
Nowadays, 97 different HSPs have been identified, subdivided into several classes based
on their molecular weight: HSPA (HSP70), HSPB (small HSP), HSPC (HSP90), HSPH (HSP110),
DNAJ (HSP40), and chaperonin families (HSPD/HSP60, HSPE, and CCT) [31]. Failure to mount
an adequate HSR is thought to underlie hypersensitivity to acute proteotoxic stress and has
been associated with age-related chronic misfolded protein [12,32]. In human AF, there are
indications that exhaustion of the HSR underlies this disease. Two studies report that higher
atrial expression levels of HSPB1 relate to short duration of AF and less extensive structural
damage. In more persistent AF stages, the HSPB1 levels become exhausted [14,22]. Further,
an inverse correlation between the amount of HSPB1 and level of myolysis was found [14].
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AF patients with high levels of HSPB1 revealed a low amount of myolysis, whereas low levels
of HSPB1 were correlated with a high amount of myolysis in atrial tissue samples. In line,
in two other studies, a comparable correlation between HSP exhaustion and AF was found.
In these studies, an inverse correlation between HSPA1A levels in atrial tissue and the incidence
of postoperative AF in patients undergoing cardiac bypass surgery was found [33,34].
Thus, studies indicate that in short-duration AF, the HSR is activated, while it dimin-
ishes over time when AF persists. As HSPs conserve proteostasis and thereby underlie
cardiomyocyte structure and function, lower levels of HSP may trigger the progression of
structural damage, paving the way to longstanding and permanent AF. Therefore, securing
HSP levels at an adequate level, for example, by treatment with HSP inducers, may limit
the expansion of the AF substrate during paroxysmal and short-term AF. In agreement with
this hypothesis, restoration of sinus rhythm in patients with permanent AF after mitral
valve surgery is correlated with HSF1 activity and induced HSPB1 levels [35]. These find-
ings emphasize the importance of HSF1 and, subsequently, HSPB1 expression to combat
AF. Several studies have been conducted to dissect the molecular mechanism underlying
HSR exhaustion in AF and have identified targets for HSR boosting.
3. Boosting HSR via the Ras Homolog Gene Family Member A (RhoA) Pathway
Why atrial cardiomyocytes are unable to mount a proper HSR in AF is possibly
related to activation of the Ras homolog gene family member A (RhoA). RhoA represents a
major stress signaling pathway, which becomes activated during AF progression [36,37].
Pathological RhoA activation has been found to suppress the cardioprotective HSR in HL-1
atrial cardiomyocytes by impairing the binding of HSF1 to HSE in the promotor sequence
of the HSP genes (Figure 1) [38]. As such, RhoA activation resulted in the inhibition of
HSP expression and hypersensitization of cardiomyocytes to proteotoxic stress. Moreover,
pre- or post-treatment with the potent HSP booster geranylgeranylacetone (GGA) could
not overcome the HSPA1A-suppressive effect of RhoA activation. Importantly, genetic
inhibition of RhoA resulted in a strong induction of the HSR, indicating that inhibition
of RhoA is a target to increase the HSR and subsequent HSP levels [38]. The mechanism
behind the prohibition of RhoA for HSF1 to bind to the HSE needs further investigation,
but this pathway opens novel insights in potential druggable targets within the RhoA
pathway, which may increase cardioprotective HSP levels in AF [38].
4. Pharmacological Boosting of HSR with Compounds
Besides inhibition of the RhoA pathway to induce HSR, other studies have tested
pharmacological pretreatment with GGA or genetic overexpression of HSPB1 to maintain
proper cardiomyocyte function and structure after tachypacing [14,36,39–43]. From a
clinical perspective, it would be highly relevant to pharmacologically halt the existing
structural damage and contractile dysfunction in atrial cardiomyocytes. This suggestion has
been further explored by pharmacological induction of HSP levels with GGA. Pretreatment
of dogs with GGA revealed protection against atrial tachypacing and (acute) ischemia-
induced impairment in electrophysiology (shortening action potential duration, L-type
Ca2+ channel current reduction), contractile function (Ca2+ transient and cell shortening
loss), and conduction velocity and consequently resulted in attenuation of AF onset and
progression [39,41]. Further, protective effects of HSPs were observed in a rabbit model for
AF induced by heart failure [42].
Notwithstanding GGA’s protective effects, the poor physicochemical properties of
GGA, including its hydrophobic nature and limited solubility, may pose disadvantages to
its druggability in AF. The gut mucosal distribution pattern owing to GGA’s hydrophobic
character hinders its systemic bioavailability [44,45] and therefore likely requires high
dosages to treat AF patients. To overcome these disadvantages, various GGA derivatives
with improved physicochemical properties compared with GGA have been synthesized
and tested for their ability to induce HSPs in HL-1 cardiomyocytes, such as GGA-31, GGA-
59, and GGA-60 [46]. Importantly, these derivatives, which are based on one geranyl group
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instead of two, revealed improved protection against tachypacing-induced Ca2+ transient
loss in HL-1 atrial cardiomyocytes. The cardioprotective actions of these HSP inducers
were HSPB1 dependent, as suppression of HSPB1 by siRNA precluded protection [46].
In addition, these GGA derivatives also protected against tachypacing-induced heart wall
dysfunction in a Drosophila melanogaster model for AF [46].
Importantly, GGA and GGA derivatives were also tested for their ability to reverse
structural damage in tachypaced HL-1 atrial cardiomyocytes [25]. In this AF recovery
model, GGA and three GGA derivatives, of which GGA-59 was superior, showed an
accelerated restoration from tachypacing-induced Ca2+ transient loss. GGA-59 likely con-
fers its protective and recovery effects on contractile dysfunction by enhancing HSF1
hyperphosphorylation with the subsequent induction of cardioprotective HSP expression
(Figure 1) [46]. However, how GGA and GGA derivatives prolong hyperphosphorylation
needs to be further elucidated. There are indications that RhoA might be involved in
this process, as post-translational prenylation with C15 (farnesyl) or C20 (geranylgeranyl)
isoprenoids mediates translocation of RhoA to the plasma membrane, which results in
activation of the downstream RhoA signaling pathway [47–49]. GGA and GGA derivatives
may compete with endogenous geranyl groups, which could lead to inhibition of physio-
logical RhoA activation, resulting in enhanced binding of HSF1 to the HSE in the promotor
region of HSP genes. Interestingly, GGA derivatives with a farnesyl group did not induce
HSP expression, suggesting that the geranyl group is required for HSP induction [46].
Further research should elucidate the role of RhoA in GGA-induced HSP expression in
cardiomyocytes.
In addition to GGA-related protective effects, other studies have described activation
of HSF1 via the semi-essential amino acid L-glutamine to boost intracellular levels of
HSPs (Figure 1) [50–52]. Moreover, L-glutamine has been described to be protective
against ischemic heart disease and heart failure by induction of HSPs [53,54]. Moreover,
a recent study investigated the role of L-glutamine on serum HSP levels in patients with
AF. This study found that HSPB1 and HSPA1A in the serum of AF patients dropped after
3 months of daily L-glutamine supplementation. Further, a strong inverse correlation was
observed between serum levels of HSPB1 or HSPA1A at baseline and after 3 months of
L-glutamine supplementation. Interestingly, metabolites in the carbohydrate, nucleotide,
and amino acid synthesis pathway were normalized in AF patients after 3 months of L-
glutamine supplementation [55]. These findings indicate that L-glutamine supplementation
affects HSP levels in AF patients and normalizes the metabolic pathways, which may
attenuate proteostasis derailment and structural damage in cardiomyocytes in clinical AF.
It has also been shown that the hydroxylamine derivate BPG-15 provides protection
against experimental AF by overexpression of endogenous dmHSP23 (homologous to
human HSPB1) in a D. melanogaster model [43]. In contrast, a mouse model for heart
failure and AF showed that the protective effect of BGP-15 was independent of HSPA1
and HSPB1, but attributed the drug’s protective role to the phosphorylation of insulin-like
growth factor 1 (IGF-1) receptor [56]. Although it has been described that hydroximic acid
derivatives can induce HSPs, the exact molecular mode of action of BGP-15 within AF has
not been elucidated yet [57]. Interestingly, a study in rats showed that BGP-15 also acts
as an inhibitor of poly(ADP)-ribose polymerase 1 (PARP-1) [58]. Since a previous study
revealed a role for DNA-damage-induced PARP1 activation to prevent structural damage
in clinical AF, BGP-15 may also protect against AF via PARP-1 inhibition [16]. Whether
HSPs are involved in the DNA-damage–PARP1 axis is unknown.
Although AF results in HSR exhaustion and cardiomyocyte dysfunction, it also may
result in cardioembolic stroke. Interestingly, studies showed that induction of HSPA1
with either HSF1 inducer TRC051384 or the HDAC6 inhibitor tubastatin A delayed the
development of thrombi in a murine model for thrombus formation [59]. HSPA1 did not
affect bleeding in mice, which is in contrast to normal anticoagulants. This is especially
relevant considering anticoagulant treatment in patients increases the risk for major bleed-
ing. Bleeding in patients could ultimately halt treatment with anticoagulants, which were
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administered to prevent cardioembolic stroke [59]. Further, supplementation of peroxisome
proliferator-activated receptor (PPAR)-γ pioglitazone was shown to upregulate HSPA1
mRNA and protein levels in atrial tissue of a rat model of AF, which resulted in attenuation
of fibrosis and morphological changes [60].
5. GGA Induces HSP Levels in Atrial Tissue of Patients Undergoing Open-Heart Surgery
A feature which makes GGA and GGA derivatives interesting as drugs is that they
only boost the HSR in cardiomyocytes under mild stress conditions [46]. This indicates that
augmentation of the HSR by GGA and its derivatives is confined to stressed cells, avoiding
potential side effects due to enhanced HSR in non-stressed cells. GGA is already marketed
in various Asian countries, despite the less favorable physicochemical therapeutic profile,
and is considered a safe drug. Therefore, GGA itself may already be further explored
in clinical AF. A recent study obtained proof of concept for its HSP-inducing effect in
human atrial tissue, since it was still unknown whether GGA can induce HSPs in the
human heart [26]. Three days of oral GGA treatment (400 mg/day), prior to coronary
artery bypass grafting surgery in patients with coronary artery disease, was associated
with a significant increase in HSPB1 and HSPA1 expression levels in right and left atrial
appendages. Furthermore, increased HSPB1 levels were present at the myofilaments in
patients treated with GGA, suggesting a beneficial effect by conservation of the myofilament
structures [26]. These findings pave the way for further studies on the role of HSP induction
by GGA and/or GGA derivatives to protect against (postoperative) AF.
6. Accelerated Restoration of Structural Damage by HSPB1: Mode of Action
As virtually all AF patients have already developed a level of structural damage at the
moment of diagnosis, it is clinically highly relevant to explore whether HSPs can reverse
deterioration. Fundamental insights into HSP-induced structural restoration of cardiomyocytes
will boost further clinical research to improve the recovery of heart function after AF conversion
and may help to prevent AF onset. Experimental and clinical AF research findings indicate that
boosting of HSPB1 seems to be crucial for the protective actions of GGA and GGA derivatives,
as suppression of HSPB1 precluded protection [39,46]. Therefore, it is of interest to dissect
the molecular mode of action of HSPB1 in recovery from AF. Is has been recognized that
HSPB1 (co)localizes at the myofilaments; stabilizes the sarcomeric proteins, including alpha-
actinin, actin, and myosin; and as such conserves cell structure [14,61,62]. By binding to and
stabilizing the sarcomeric proteins, HSPB1 may shield the contractile proteins from AF-induced
cleavage by cysteine proteases, including calpain 1 (Figure 1) [43,63,64]. Experiments with
post-tachypacing-induced HSP expression reveal that HSPB1 also accelerates recovery. HL-1
cardiomyocytes post-treated with GGA-59 revealed accelerated recovery from tachypacing-
induced Ca2+ transient loss and restored mRNA and protein levels of (acetylated) α-tubulin,
as well as protein levels of cardiac troponin I and troponin T. Similar protective effects were
observed after overexpression with recombinant HSPB1 with Ca2+ transient loss and tubulin
expression; however, this did not affect cardiac troponins [25].
Furthermore, post-treatment with GGA-59 enhanced recovery of depolymerized
(acetylated) α-tubulin fractions, which coincided with elevated HSPB1 binding. GGA-59
treatment did not change tachypacing-induced calpain activity but did normalize HDAC6
activity [25]. Interestingly, HDAC6 activity was previously found to result in deacetylation
of the microtubule network and AF promotion in experimental cardiomyocyte (Drosophila)
and dog models for AF [65]. These findings point to HSPB1 protecting the microtubule
network, possibly by direct binding of HSPB1 to HDAC6 (Figure 1) [66], and suppressing
its activity, resulting in prevention of deacetylation, depolymerization, and subsequent
degradation of α-tubulin by calpain [25]. Since overexpression of recombinant HSPB1
caused a restoration of post-tachypacing α-tubulin expression, it can be hypothesized that
HSPB1 directly influences α-tubulin transcription. Moreover, a previous study showed
that HSPB1 interacted with the transcription factor SP1 and thereby regulated gene tran-
scription in experimental cell culture models [67]. However, whether HSPB1 interacts with
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transcription factors that target tubulin genes remains unknown. Another explanation
for the restoration of α-tubulin mRNA expression might be the indirect effect of HSPB1
on the microtubule network, as depolymerized α-tubulin can degrade and destabilize
α-tubulin mRNA associated with ribosomes [68–70]. It remains to be elucidated whether
this autoregulatory mechanism is activated upon tachypacing of the atrial cardiomyocyte.
Thus, induction of HSPB1 levels accelerates recovery from tachypacing-induced structural
damage and contractile dysfunction in HL-1 cardiomyocytes, indicating that HSP induction
is an interesting target to potentially reverse AF-induced remodeling.
7. Potential Protective Role of HSPA in AF
The HSPA protein family has an essential role in proteostasis, and a protective role in AF
has been described. In an experimental study in mice, it was observed that induction of HSPA1
prevents angiotensin-II-induced AF by limiting atrial fibrosis formation [71]. Interestingly, in a
dog model, it was shown that supplementation of angiotensin (1–7) protects against tachypacing-
induced sustained AF and correlates with a decrease in HSPB1 mRNA and protein levels in the
left and right atria [72]. Angiotensin (1–7) likely antagonizes angiotensin II and in turn prevents
atrial remodeling, thereby avoiding an HSR [72]. Furthermore, a recent study discovered
the interplay between HSPA and a single nucleotide polymorphism (SNP) in nuclear lamins.
The SNP mutation p.R399C in LMNA was found in a sporadic case during a whole-exome
sequencing of more than 600 patients with “lone” AF. LMNA p.R399C was suggested to impair
the interaction of lamin A/C with nuclear pore complex protein (NUP155). Moreover, impaired
interaction between lamin A/C and NUP155 was found to prevent the export of HSPA1,
and potentially also other HSPs, out of the nucleus (Figure 1) [73]. As such, mutations in nuclear
filaments may underlie the development of clinical AF [73–77]. In line, recent experiments
performed in DLD-1 colorectal epithelial cells showed not only attenuated HSPA1 import upon
depletion of lamin A/C but also an impaired transcription of HSPA1, indicating a key role for
mutant-lamin-induced HSPA suppression [78]. As mutations in lamin A/C are well described
in individuals diagnosed with AF and are linked to various cardiomyopathies [75,76,79–81],
impairment of nuclear export of HSPA to the cytosol may represent an important pathway in
mutant-lamin-induced AF [34,82].
Although not regulated by HSF1, a cardioprotective role for HSPA5 was previously iden-
tified in AF [83]. HSPA5 is located in the endoplasmic reticulum (ER) of the cardiomyocyte and
attenuates AF-induced ER stress and autophagy, thereby diminishing structural remodeling
(Figure 1) [83]. Interestingly, HSPA5 was found to be a hub–bottleneck gene in a recent meta-
analysis of transcriptome data related to AF [84]. HSPA5 was consistently downregulated,
which further establishes the protective function of HSPA5 normalization in AF [84].
8. HSPs as Biomarkers in AF
Currently, accurate staging of AF lacks sophisticated diagnostic tools, which hampers
the selection of patient-tailored therapy [9]. Consequently, there is an urgent need to identify
biomarkers which may help to stage AF. Serum and atrial tissue samples of patients with
or without AF were enrolled in the HALT&REVERSE trial in order to test the potency of
HSPs as a potential biomarker [85]. This trial investigated whether HSP levels in serum
discriminate between control and the various stages of AF and predict AF recurrence
after treatment. Importantly, serum HSPA1, HSPB1, HSPB7, and HSPD1 levels did not
discriminate between the presence or stage of AF, nor did it identify patients at risk of AF
recurrence after electrical cardioversion or pulmonary vein ablation [17]. However, follow-
up serum HSPB1 levels predict AF recurrence in patients undergoing ablative therapy.
Here, serum HSPB1 levels significantly increased at 3, 6, and 12 months post-ablation
compared with patients without AF recurrence within 1 year post-ablation [17]. These results
suggest that HSPB1 levels may be useful in predicting recurrence of AF after ablative
therapy. These results are further supported by other studies showing an association
between increased atrial tissue levels of HSPA1 and HSPB1 and restoration of sinus rhythm
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in patients after mitral valve surgery [86], and that high HSPB1 levels in blood predict sinus
rhythm maintenance after catheter ablation in patients with paroxysmal AF [87].
Whether serum HSPB1 levels can also be used to select patients for HSP-inducing therapy
remains to be elucidated. As mentioned above, AF patients with high levels of HSPB1 at
baseline and who were treated for 3 months with the HSP-inducing compound L-glutamine
showed significant reduction in serum HSPB1 levels accompanied with normalization of
metabolite levels compared with patients with low HSP levels at baseline. This all indicates
that serum HSPB1 levels may guide patient-tailored therapy [55]. In addition, further research
should elucidate whether the HSP levels in serum correlate with HSP levels in atrial tissue and
the degree of electrical conduction abnormalities and voltage changes. This could also shed
light on whether increased HSP levels are a result of AF or precedes AF (recurrence). Studies
with longitudinal blood sampling (for HSP measurements) and continuous monitoring of
electrical parameters may pinpoint possible associations.
9. Conclusions
The current clinical treatment and diagnostic staging of AF require further improve-
ment. Pharmacological boosting of HSP levels, by inhibition of the RhoA pathway and
enhancing binding of HSF1 to HSP genes, in atrial tissue may aid in the accelerated re-
covery from cardiomyocyte damage and, as such, may result in halting of AF. Identified
mechanisms of action include prevention of microtubule disruption by HDAC6 and cleav-
age by calpain and increase in microtubule transcription. Findings also indicate that HSP
levels in serum may stage AF and identify patients at risk of AF recurrence after treatment.
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